Omeros Co. (NASDAQ:OMER) Shares Purchased by SG Americas Securities LLC

SG Americas Securities LLC increased its stake in shares of Omeros Co. (NASDAQ:OMER) by 59.3% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 30,438 shares of the biopharmaceutical company’s stock after buying an additional 11,333 shares during the quarter. SG Americas Securities LLC’s holdings in Omeros were worth $100,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. BlackRock Inc. boosted its position in shares of Omeros by 258.0% during the 2nd quarter. BlackRock Inc. now owns 4,154,952 shares of the biopharmaceutical company’s stock valued at $22,603,000 after acquiring an additional 2,994,468 shares during the last quarter. State Street Corp increased its holdings in shares of Omeros by 344.7% during the 2nd quarter. State Street Corp now owns 1,139,199 shares of the biopharmaceutical company’s stock worth $6,197,000 after buying an additional 883,025 shares during the last quarter. Millennium Management LLC raised its position in shares of Omeros by 188.1% during the 2nd quarter. Millennium Management LLC now owns 1,220,782 shares of the biopharmaceutical company’s stock valued at $3,357,000 after buying an additional 797,034 shares during the period. CI Private Wealth LLC acquired a new position in Omeros in the fourth quarter valued at approximately $1,453,000. Finally, Geode Capital Management LLC grew its position in Omeros by 98.4% in the second quarter. Geode Capital Management LLC now owns 1,253,711 shares of the biopharmaceutical company’s stock worth $6,820,000 after acquiring an additional 621,819 shares during the period. 48.79% of the stock is currently owned by hedge funds and other institutional investors.

Omeros Price Performance

Shares of OMER stock opened at $3.05 on Friday. Omeros Co. has a 1-year low of $0.92 and a 1-year high of $7.80. The firm has a market cap of $176.72 million, a PE ratio of -1.62 and a beta of 1.34. The company has a 50-day moving average of $3.88 and a two-hundred day moving average of $3.01.

Analyst Ratings Changes

Separately, StockNews.com upgraded Omeros from a “sell” rating to a “hold” rating in a research report on Wednesday, April 3rd.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.